Interesting that the current Holy Grail approach is a dual-mechanism drug in a pill form (sound familiar?):

''It’s possible that pairing fluvoxamine with a drug that interferes with viral replication, such as Merck’s upcoming antiviral molnupiravir, could be even more effective, Mills says. “It would be fascinating to look at whether or not the antiviral and [anti-inflammatory drugs combined] give you much greater treatment benefits than either alone.”